Abstract Purpose: DNA replication licensing factors and Aurora kinases play critical roles in maintaining genomic integrity. We used multiparameter analyses of these cell cycle regulatory proteins to investigate their role in the progression of epithelial ovarian carcinoma (EOC). Experimental Design: In a cohort of 143 patients, we linked the protein expression profiles of the proliferation marker Ki67, the replication licensing factors Mcm2 and geminin, and the Aurora A and B kinases to tumor DNA ploidy status and clinical outcome. Results: Ki67, Mcm2, geminin, and Aurora A and B are significantly associated with tumor grade and ploidy status (P < 0.0001). Aurora A and its substrate H3S10ph are also significantly associated with Federation of International Obstetricians and Gynecologists tumor stage (P = 0.006 and P = 0.002, respectively). Aurora A and tumor ploidy status are predictive of disease-free survival in this cohort [hazard ratio (HR), 1.29; 95% confidence intervals (95% CI), 1.06-1.58, P = 0.01and HR, 1.80 (1.05-3.08), P = 0.03, respectively], with Aurora A of particular prognostic importance in early stage disease [HR, 1.72 (1.19-2.48), P = 0.004 for disease-free survival and HR, 1.81 (1.14-2.87), P = 0.01for overall survival]. Conclusions: Our data show that Ki67, Mcm2, geminin and Aurora A and B can be used as an adjunct to conventional prognostic indicators and as an aid to develop a tumor progression model for EOC. Dysregulation of Aurora A seems to be an early event in EOC with a key role in tumor progression. In view of present drug development programs for specific Aurora kinase inhibitors, our findings have important implications for the use of Aurora A as a biomarker and as a potential therapeutic target.
Epithelial ovarian carcinoma (EOC) is the fourth most common cancer in women in the U.S. and the U.K. (1) . It often presents with advanced disease, and despite improvements in drug therapy, survival is poor (2) . Tumor stage is the most important prognostic factor. Residual disease after surgery, histologic subtype, and tumor grade also predict survival (3, 4) , but give little information about the biological variables responsible for stage progression and outcome. The pathogenesis of EOC remains poorly understood and a clear model of tumor progression has not been firmly established. DNA damage in the ovarian surface epithelium due to repetitive ovulation, defective DNA repair mechanisms, and dysregulation of cell proliferation are all postulated to be involved (5) . Aggressive tumors are characterized by increased proliferation and chromosomal aberrations (6) , with f45% of stage I and 75% of stage III and IV tumors exhibiting aneuploidy (7) . Controversy remains as to whether measurement of DNA ploidy has a proven role in the clinical management of EOC. Several studies, however, have shown that tumor ploidy status is of prognostic significance in both early and advanced stage disease (8) .
Genomic instability, a hallmark of malignancy, leads to the acquisition of alterations in specific genes (9) . Such alterations may arise from gene mutations and microsatellite instability, or from gross changes in DNA content due to chromosomal instability, which in turn is intricately linked to tumor aneuploidy. Whether aneuploidy drives tumor progression or is a consequence of malignancy has long been a matter of debate (10, 11) . However, recent accumulating evidence has shown that specific cell cycle regulatory proteins involved in DNA replication and mitosis play crucial roles in maintaining genomic integrity (12, 13) .
Precise duplication of DNA during each cell division cycle is essential for genomic stability and is achieved through tightly regulated initiation events. DNA replication initiation depends on the assembly of prereplicative complexes at replication origins during late mitosis and early G 1 phase. Prereplicative complex assembly involves sequential binding of origin recognition complex, Cdc6, Cdt1, and Mcm2-7 to origins and renders chromatin ''licensed'' for DNA synthesis during S phase. At the G 1 -S transition, CDKs and the Cdc7/ASK kinase trigger a conformational change in the prereplicative complexes resulting in the recruitment of DNA polymerase a and elongation factors and initiation of DNA synthesis (14) . We and others have shown that the regulation of Mcm2-7 protein levels provides a powerful downstream mechanism for controlling cell proliferation in human tissues (15) . Mcm2-7 dysregulation is an early event in multistep tumorigenesis, and these biomarkers are now being widely exploited in cancer screening and diagnosis (16) . Inhibition of prereplicative complex reassembly, which ensures that origins are fired once-and-only-once per cell cycle, is critical for maintaining genomic integrity. The licensing repressor geminin is expressed at high levels during S-G 2 -M phases and blocks Mcm2-7 reloading onto chromatin through its interaction with Cdt1 (17) . In human cell populations in vivo, we have shown that geminin expression is also restricted to S-G 2 -M phases (18, 19) . Importantly, depletion of geminin results in profound genomic instability with overreplication of DNA, resulting in the emergence of cells with giant aneuploid nuclei, which are the morphologic/pathologic hallmarks of aggressive cancers (12) . Inactivation of geminin also causes centrosome overduplication, which, together with abrogated G 2 -M checkpoint mechanisms, results in multiple mitotic defects that may promote chromosome missegregation and aneuploidy (20) . These findings emphasize the key role that geminin plays in maintaining genomic integrity at multiple stages of the cell cycle.
The Aurora kinases are important regulators of several stages of mitosis, including centrosome maturation and separation, chromosome orientation and segregation, and cytokinesis (13, 21) . Dysregulation of Aurora A and Aurora B has been implicated as a cause of malignant transformation in cultured mammalian cells and in the development of aneuploidy (22 -24) . These kinases are frequently overexpressed in human tumors (25 -28) , with the gene for Aurora A located at 20q13.2 being commonly amplified in various epithelial malignant tumors including EOC (29) . Like geminin, endogenous levels of the Aurora kinases are tightly regulated in a cell cycledependent manner, with low levels at G 1 -S, accumulation during G 2 -M, and rapid degradation at the end of mitosis (22, 30, 31) . Their functional role as essential regulatory kinases has highlighted the Aurora family members as promising targets for anticancer drug development.
In light of the biological, prognostic, and therapeutic implications of these cell cycle regulators in tumorigenesis, we have investigated their role in the progression of EOC. We have used multiparameter analysis of Mcm2, geminin, Aurora A and Aurora B, and their substrate histone H3 (32, 33) to study the cell cycle kinetics of this tumor type in vivo. Furthermore, we have linked the protein expression of these biomarkers to genomic instability, clinicopathologic variables, and clinical outcome in a series of 143 patients. Our data provide new insights into the biological mechanisms underlying tumor progression in EOC, and how these biomarkers might be exploited to predict tumor behavior. Moreover, our findings provide further target validations for novel therapeutic approaches targeting the DNA replication licensing pathway and the mitotic machinery (34, 35) . Antibodies. Rabbit polyclonal antibody against human geminin was generated as described (18) . Ki67 monoclonal antibody (clone MIB-1) was obtained from DAKO, Mcm2 monoclonal antibody (clone 46) was from BD Transduction Laboratories, Aurora A monoclonal antibody NCL-L-AK2 (clone JLM28) was from Novocastra Laboratories, Aurora B polyclonal antibody Ab2254 was from Abcam PLC, and histone H3 phosphorylated on serine 10 (H3S10ph) polyclonal antibody was from Upstate.
Materials and Methods
Cell culture and synchronization. HeLa S3 cells (European Collection of Animal Cell Cultures 87110901) were cultured and synchronized as described (36) . Cell cycle synchronization was verified by flow cytometry of isolated nuclei as previously described (37) .
Preparation of protein extracts and immunoblotting. HeLa S3 cells were harvested by treatment with trypsin, washed in PBS, and resuspended in lysis buffer [50 mmol/L Tris-Cl (pH 7.5), 150 mmol/L NaCl, 20 mmol/L EDTA, 0.5% NP40] at 2 Â 10 7 cells/mL. After incubation on ice for 30 min, the lysate was clarified by centrifugation (13,000 Â g, 15 min, 4jC). Lysates were separated by 4% to 20% SDS-PAGE (75 Ag protein/well) and immunoblotted as previously described (36) . Blocking, antibody incubations, and washing steps were done using the following conditions: PBS/0.1% Tween 20/5% milk for Mcm2 and Aurora A, PBS/1% Tween 20/10% milk for geminin, and PBS/5% milk for Aurora B and H3S10ph.
Immunohistochemistry. Archival formalin-fixed, paraffin-embedded tissue obtained at initial diagnosis was available for all patients, and for each specimen, a block was chosen that contained a representative sample of invasive tumor. Consecutive serial sections cut from each paraffin-embedded tissue block were used for immunohistochemistry. Three-micrometer sections were cut onto Superfrost Plus slides (Vision BioSystems), dewaxed in xylene, and rehydrated through graded alcohol to water. Tissue sections were pressure-cooked in 0.1 mol/L citrate buffer at pH 6.0 for 2 min and immunostained using the Bond Polymer Define Detection kit and Bond-X automated system (Vision BioSystems). Primary antibodies were applied at the following dilutions: Ki-67 (1:100), Mcm2 (1:2,000), geminin (1:600), Aurora A (1:50), Aurora B (1:200), and H3S10ph (1:300). Coverslips were applied with Pertex mounting medium (CellPath Ltd.). Incubation without primary antibody was used as a negative control and colonic epithelial sections as positive controls.
Protein expression profile analysis. Protein expression analysis was done by determining the labeling index of the markers in each tumor, as previously described (38, 39) . Slides were evaluated at low-power magnification (Â100) to identify regions of tumor with the highest intensity of staining. From these selected areas, three to five fields at Â400 magnification were captured with a charged coupled device camera and analysis software (SIS). Images were subsequently printed for quantitative analysis, which was undertaken with the observer unaware of the clinicopathologic variables. Both positive and negative cells within the field were counted and any stromal or inflammatory cells were excluded. Criteria for the identification of positive cells were dependent on the biomarker. For Ki67, Mcm2, geminin, Aurora B, and H3S10ph, cells with any degree of nuclear staining were scored positive. For Aurora A, cells with any degree of nuclear or cytoplasmic staining were scored positive (27) . A minimum of 500 cells were counted for each case. The labeling index was calculated using the following formula: labeling index = number of positive cells / total number of cells Â 100. Reassessment of 10 randomly selected cases by an independent assessor showed high levels of agreement.
DNA image cytometry. For each case, one 40-Am section of paraffinembedded tissue obtained from the same block as that assessed by immunohistochemistry was used to prepare nuclei as described (40, 41) . The Fairfield DNA Ploidy System (Fairfield Imaging, Ltd.) was used for image processing, analysis, and classification as previously described (40) . Lymphocytes and plasma cells were included as internal controls and 40-Am sections of high-grade bladder tumor and normal colonic tissue as external controls for aneuploid and diploid populations, respectively. Histograms were classified according to published criteria (40, 41) . Histograms were classified by two independent assessors with a high level of agreement without knowledge of clinicopathologic variables. For statistical analysis, tetraploid and polyploid tumors were grouped together with aneuploid tumors.
Statistical analysis. Spearman's rank correlation coefficient was used to examine associations between biomarkers. Relationships between biomarker expression and tumor grade, stage, and ploidy status were assessed using nonparametric Jonckheere-Terpstra and Mann-Whitney U tests as appropriate. Data were then summarized as the median value and interquartile range of labeling indices observed across the cohort. Analysis of disease-free and overall survival data was carried out using Kaplan-Meier plot (using tertiles for biomarkers), log-rank test, and Cox regression (treating biomarkers as continuous variables unless stated otherwise). For each biomarker, the cohort was divided into tertile groups on the basis of the labeling index. Within each tertile group, the proportion remaining that was either disease-free or alive, for disease-free and overall survival, respectively, was calculated using the Kaplan-Meier method. Hazard ratios (HR) with 95% confidence intervals (95% CI) for biomarkers were first estimated unadjusted, and then adjusted for age, grade and stage. Patients with incomplete data were excluded from the multivariate analysis. Candidate biomarkers are listed in Supplementary Table S1. All tests were two-sided and used a significance level of 0.05 and no allowances were made for multiple hypothesis testing. Analysis was carried out using SPSS 12.0 for Windows (SPSS, Inc.).
Results

Validation of biomarker multiparameter analysis and its biological implications
The monospecificity of antibodies against Mcm2, geminin, Aurora A, Aurora B, and H3S10ph was confirmed in total cell extracts from asynchronous HeLa S3 cells by detection of a single protein with a molecular mass consistent with the reported electrophoretic mobility of the corresponding human antigen (Fig. 1A) . HeLa S3 cells were selected in the first instance for in vitro studies as this line has well characterized cell cycle phase transit times and established synchronization protocols. Total cell lysates from synchronized cells were immunoblotted with the characterized antibodies (Fig. 1B) . Mcm2 levels did not vary significantly during passage through the cell cycle, whereas geminin expression was restricted to S-G 2 -M as previously reported (18) . Aurora A levels increased during S phase and peaked during mitosis, with degradation occurring 2 to 4 h after release from mitotic arrest. Similarly, Aurora B levels were negligible during G 1 phase, increased gradually during S phase to reach a peak during G 2 -M, and decreased after mitosis. The presence of H3S10ph was restricted to mitosis as previously reported (42) , consolidating the rationale for its use as a mitotic marker. Identical cell cycle -dependent expression of these biomarkers was observed in synchronized SK-OV3 ovarian cancer cells (data not shown). Because Ki67 is expressed throughout the cell cycle in proliferating cells and geminin expression is restricted to the S-G 2 -M phase, we have proposed that the geminin/Ki67 ratio may be used as an indicator of the relative length of G 1 , and therefore, the rate of cell cycle progression (18, 19) . The data described above confirms that cell cycle -dependent expression of Aurora A and Aurora B also enables the use of their ratios with Ki67 as indicators of cell cycle progression. Increased geminin expression has been noted in several malignancies and correlates positively with cell proliferation (43) . Notably, this increased expression is always restricted to the S-G 2 -M phase, even in highly aggressive tumors. Our in vitro findings therefore also indicate that an increase in the relative ratio between Aurora A or Aurora B and geminin (ratio > 1) would be indicative of overexpression of the kinase during the cell cycle.
To assess the prognostic significance of our in vitro findings and their biological implications in EOC, we analyzed the expression of biomarkers in a series of 143 cases (Fig. 1C) . Protein expression was also studied in five cases of normal ovarian tissue. Expression of the biomarkers was extremely low (<4%) in normal ovarian surface epithelium, in keeping with its lowered proliferative capacity (data not shown). By contrast, EOC showed high levels of biomarker expression, indicative of cell cycle re-entry and proliferation. Next, we examined the correlations between pairs of biomarkers across the tumor series. The expression levels of Aurora A and Aurora B showed a strong positive correlation with those of their substrate The clinicopathologic characteristics of the study cohort are summarized in Table 1 . To investigate the relationship between the biomarkers and genomic instability, we linked their expression profiles to tumor DNA content. There was a highly Research.
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All six biomarkers were also strongly associated with tumor grade (Table 3) ; however, there is some overlap in the distributions of biomarker levels between grades (e.g., Aurora A levels; Supplementary Fig. S1 ). These data confirm an increasing proportion of cycling cells with increasing tumor anaplasia, but also indicate that the biomarkers do not fully distinguish between grades for all patients within each grade. In keeping with these findings, a highly significant association between tumor grade and ploidy status was found (P < 0.001). The ratios among geminin/Ki67, Aurora A/Ki67, Aurora B/Ki67, and H3S10ph/Ki67 were also significantly associated with tumor differentiation, indicative of an accelerated rate of cell cycle progression in high-grade tumors. By contrast, and consistent with our findings in other tumor types (38, 39) , the Mcm2/Ki67 ratio decreased with increasing tumor grade. This reflects a shift in the proportion of DNA replication licensed but nonproliferating cells in well-differentiated tumors to actively cycling cells in poorly differentiated tumors. The positive correlation between geminin expression and increasing tumor anaplasia and genomic instability indicates that this licensing repressor does not behave as a tumor suppressor in EOC. This has also been observed in other tumor types (19) , in which the number of geminin-expressing cells is proportional to the cell proliferation index (43) . A significant association was found between Aurora A, H3S10ph, Aurora A/Ki67, H3S10ph/Ki67 and tumor stage (Table 4 ). In keeping with a previous study (27) , this suggests that Aurora A dysregulation might be a key event in early epithelial ovarian tumorigenesis and progression to advanced stage disease. Furthermore, advanced stage disease was significantly associated with an increase in the Aurora A/ geminin ratio (P = 0.04; Table 4 ), also supporting a link between Aurora A dysregulation and tumor progression.
Relationship between biomarkers, tumor DNA ploidy status, and patient outcome Univariate analysis. Aurora A (P = 0.01; Fig. 2A ), Aurora A/Ki67, Aurora B/Ki67, and H3S10ph (Supplementary Table S1 ) were all significantly associated with shorter disease-free survival but not overall survival. We subdivided our series into two groups; early stage disease (FIGO stages I and II) and advanced stage disease (FIGO stages III and IV) to more precisely define the specific subgroups for which the biomarkers may have particular prognostic importance. Both Aurora A and the Aurora A/Ki67 ratio were strongly predictive of shorter disease-free survival [HR, 1.72 (1.19-2.48), P = 0.004 (Fig. 2C) ; HR, 1.59 (1.13-2.24), P = 0.008, respectively] and overall survival [HR, 1.81 (1.14-2.87), P = 0.01 (Fig. 2E) . Although several biomarkers were significant prognostic factors in univariate analysis, none was a significant predictor of disease-free or overall survival after adjustment for age, grade, and stage. This is due partly to the highly significant associations between the biomarkers and tumor grade and stage, making it difficult to separate their independent effects.
Discussion
This study was undertaken to gain further insight into biological markers of EOC that may be of prognostic and predictive value and could lead to a greater understanding of its pathogenesis. Our findings show that the Mcm2 and geminin replication licensing factors, and the Aurora A and B kinases, together with their substrate H3S10ph (33, 34) , are of prognostic value in EOC. The association found between tumor differentiation and this set of biomarkers has been noted in several other malignancies (18, 19, 27, 38, 45, 46) and has implications for their use as proliferation markers with potential for further improvements in the current grading system. Our multiparameter analysis shows that it could also be used to provide information about cell cycle progression in patient tumor samples, data that translate into important prognostic information. These findings are in keeping with our more limited analysis of licensing factors in breast and renal cell cancer (38, 39) . Furthermore, the highly significant association found between this set of biomarkers and tumor ploidy status suggests that dysregulation of the licensing machinery and mitotic kinases is intricately linked to the development of genomic instability in EOC. Aurora A plays a regulatory role in several key stages of the G 2 -M transition (13, 21) and compelling evidence exists for its oncogenic potential (22, 25 -29, 47) . Here, we report an intriguing link between aberrant regulation of Aurora A and EOC progression. Our data show highly significant associations between Aurora A, H3S10ph and tumor FIGO stage, supporting a previous report that Aurora A dysregulation might be an early event in epithelial ovarian carcinogenesis (27) and suggesting that its dysregulation might play a role in the progression to advanced disease. In line with these findings, the Aurora A/geminin ratio is significantly higher in advanced stage tumors, which also suggests that Aurora A overexpression might play a role in or might be a result of tumor progression. In vivo, it is likely that such overexpression is regulated by not only gene amplification but also other mechanisms such as transcriptional activation and suppression of protein degradation (21) .
Our data suggest that multiparameter analysis of Aurora A and H3S10ph allows molecular staging which could be used to complement clinical staging methods. FIGO stage is an important prognostic indicator in EOC, however, surgical and radiological staging methods have their limitations. Randomized trials have shown that adjuvant chemotherapy is of particular benefit in suboptimally staged patients with stage I disease (48) . However, in a recent large randomized controlled trial, only 34% of patients were optimally staged according to guidelines (49) . In those patients who were inadequately staged, these biomarkers might provide supportive evidence of either true stage I or more advanced disease, assisting a decision about the use of adjuvant chemotherapy. The findings of the ICON 1/ACTION trials suggested a small overall benefit for adjuvant chemotherapy (50), but it remains unclear which adequately staged patients with stage I disease really need chemotherapy. The additional prognostic information from Aurora A and H3S10ph should be tested in a larger data set of patients with stage I cancer in which outcome data and chemotherapy usage are known. However, it should be noted that the prognostic value of these biomarkers does not have independent prognostic importance for more advanced disease. Aurora A, H3S10ph, and genomic instability are also significant predictors of disease-free survival in this study cohort. Further subgroup analysis showed that Aurora A and tumor ploidy status are predictive of disease-free survival (with Aurora A expression also predicting overall survival) in early disease. However, this association was reduced when prognostic factors such as age and stage were taken into account. By contrast, these variables lost their predictive value in advanced disease [e.g., HR for Aurora A dropped from 1.72 (1.19-2.48) in early stage disease to 1.06 (0.81-1.37) for advanced stage disease], suggesting that other biological factors may take precedence in influencing relapse and outcome in these patients. In addition, the complexity and heterogeneity of treatment regimens might mask the predictive value of these biomarkers in advanced stages. Several studies have shown the prognostic significance of DNA ploidy in EOC (8) , however, the underlying mechanisms remain unclear. Taken together, our data are supportive of a biological mechanism by which Aurora A dysregulation at an early point during tumorigenesis might contribute to genetic instability, resulting in aggressive tumors and shorter survival in a subgroup of patients with early stage disease.
DNA replication licensing factors and mitotic kinases are critical regulators of cell cycle progression, and thus, are the focus of current therapeutic drug development programs (32, 35) . Here, we have shown that multiparameter expression analysis of core regulators of the G 1 -S and G 2 -M transitions allows the assessment of the rate of cell cycle progression in individual patient tumor samples, variables linked to the biological behavior of these tumors. This type of analysis could be used as a predictive test for small molecules targeting the cell cycle machinery or upstream growth signal transduction pathways that accelerate cell cycle progression. Moreover, the observation that Aurora A expression does not fully distinguish between grades shows that traditional clinicopathologic variables do not always allow the prediction of therapeutic response, supporting the concept of coevolution of biomarker and individualized targeted therapy. In view of the recent development of specific Aurora kinase inhibitors, our data have important implications-prognostic, predictive, and .3%) and disease-free survival across the whole series; log-rank test, P = 0.01. B, tumor ploidy status and disease-free survival across the whole series; log-rank test, P = 0.03. C, Aurora A (lower tertile <8.7%, middle tertile 8.7-19.6%, upper tertile >19.6%) and disease-free survival in early stage subgroup; log-rank test, P = 0.004. D, tumor ploidy status and disease-free survival in early stage subgroup; log-rank test, P = 0.04. E, Aurora A (lower tertile <8.7%, middle tertile 8.7-19.6%, upper tertile >19.6%) and overall survival in early stage subgroup; log-rank test, P = 0.01. F, tumor ploidy status and overall survival in early stage subgroup; log-rank test, P = 0.08. therapeutic-for the use of Aurora A as a biomarker and potential therapeutic target. These findings need to be confirmed in a large patient cohort, and it will be of interest to determine whether this form of multiparameter cell cycle analysis is of diagnostic utility in other tumor types.
